Advertisement Bristol-Myers dual oral therapy shows efficacy in HCV patients - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Bristol-Myers dual oral therapy shows efficacy in HCV patients

Bristol-Myers Squibb's dual direct-acting antiviral (DAA) regimen of daclatasvir and asunaprevir showed sustained virologic response (SVR) in genotype 1b hepatitis C (HCV) patients.

Daclatasvir is an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor.

In the Phase II open-label clinical trial (AI447-017), patients were divided into two treatment groups: Group A consisted of 21 genotype 1b prior null responders and Group B consisted of 22 genotype 1b patients medically ineligible for peginterferon alfa and ribavirin (alfa/RBV) or with prior intolerance to alfa/RBV.

The study’s primary endpoint was the proportion of patients with sustained virologic response 12-weeks following treatment (SVR12).

A total of 77% of patients achieved SVR12, while 91% and 64% of patients in Group A and Group B respectively, achieved SVR24.